← Back to Search

Device

Remotely Supervised tDCS and Word-Naming Practice for Primary Progressive Aphasia

Phase 2
Waitlist Available
Led By Leigh Charvet, PhD
Research Sponsored by NYU Langone Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, month 6
Awards & highlights

Study Summary

This trial will evaluate if a combination of remotely supervised brain stimulation and language skills practice can help people living with PPA. No established treatments exist.

Eligible Conditions
  • Primary Progressive Aphasia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, month 6
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, month 6 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Participants who Complete 16 out of 20 Study Visits
Secondary outcome measures
Change in Aphasia Communication Outcome Measure (ACOM) Score
Change in Boston Naming Test (BNT)-Short form Score
Change in Controlled Oral Word Association Test (COWAT) Score
+6 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Remotely Supervised tDCS and Word-Naming PracticeExperimental Treatment2 Interventions
At each session, the tDCS device will deliver 2.0 mA electric current for 30 minutes over the left frontotemporal lobe with focus on the inferior frontal gyrus (IFG). Participants will receive 20 intervention sessions over the course of the interventional period (4 weeks) on weekdays (Monday-Friday). During the stimulation period, participants will engage in a picture-naming exercise as guided by the study tDCS clinicians.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Transcranial Direct Current Stimulation (tDCS)
2016
Completed Phase 2
~2100
Word-Naming Activity
2022
Completed Phase 2
~10

Find a Location

Who is running the clinical trial?

NYU Langone HealthLead Sponsor
1,367 Previous Clinical Trials
839,711 Total Patients Enrolled
Leigh Charvet, PhDPrincipal InvestigatorNYU Langone Health
4 Previous Clinical Trials
82 Total Patients Enrolled

Media Library

Transcranial Direct Current Stimulation (tDCS) (Device) Clinical Trial Eligibility Overview. Trial Name: NCT05615922 — Phase 2
Primary Progressive Aphasia Research Study Groups: Remotely Supervised tDCS and Word-Naming Practice
Primary Progressive Aphasia Clinical Trial 2023: Transcranial Direct Current Stimulation (tDCS) Highlights & Side Effects. Trial Name: NCT05615922 — Phase 2
Transcranial Direct Current Stimulation (tDCS) (Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05615922 — Phase 2
Primary Progressive Aphasia Patient Testimony for trial: Trial Name: NCT05615922 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this clinical experiment open to individuals aged 55 and above?

"This medical trial's eligibility criteria necessitates that applicants be between 45 and 80 years old."

Answered by AI

Who is eligible to take part in this research initiative?

"This clinical trial is searching for 30 participants with primary progressive aphasia (PPA) between 45 and 80 years old. To be eligible, they must have a PPVT score that falls below -1 standard deviation, WAIS-IV Matrix Reasoning T score lower than 20, English language fluency sufficient to take part in the study procedures, stable internet access and email service (WiFi "hotspot" provided if necessary), diagnosis of PPA's logopenic or semantic variant."

Answered by AI

How many participants are receiving treatment through this investigation?

"Affirmative. According to the clinicaltrials.gov website, this medical study is currently recruiting patients who meet its criteria - with a total of 30 needed from one site. This trial was initially posted on November 1st 2022 and most recently edited on November 8th 2022."

Answered by AI

Has the FDA authorized Remotely Supervised tDCS and Word-Naming Practice?

"According to our team at Power's assessment, the safety of Remotely Supervised tdcs and Word-Naming Practice is estimated as a 2 due to this being a Phase 2 trial. This indicates there are some data points supporting its security but none that demonstrate efficacy."

Answered by AI

Are there any active recruitment opportunities for this clinical trial?

"Affirmative. As per information on clinicaltrials.gov, this trial is actively welcoming patients to take part in its research. The investigation was first publicized on November 1st 2022 and has been revised most recently on the 8th of that same month. Only 30 individuals need to be enrolled from a single medical facility."

Answered by AI

Who else is applying?

What state do they live in?
Indiana
New York
What site did they apply to?
NYU Langone Health
What portion of applicants met pre-screening criteria?
Met criteria
Did not meet criteria
How many prior treatments have patients received?
0

Why did patients apply to this trial?

For over one year, I have had difficulty with memory and speech. It has declined over that year.
PatientReceived 2+ prior treatments
Recent research and studies
clinicaltrials.govStudy
Remotely Supervised Transcranial Direct Current Stimulation (tDCS) for Primary Progressive Aphasia (PPA)
2022. "Remotely Supervised Transcranial Direct Current Stimulation (tDCS) for Primary Progressive Aphasia (PPA)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05615922.
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top